<SEC-DOCUMENT>0000886744-25-000007.txt : 20250507
<SEC-HEADER>0000886744-25-000007.hdr.sgml : 20250507
<ACCEPTANCE-DATETIME>20250507070542
ACCESSION NUMBER:		0000886744-25-000007
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250507
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250507
DATE AS OF CHANGE:		20250507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		25919241

	BUSINESS ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>gern-20250507.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:36b68b42-154c-41c5-9cff-b46b921c2a16,g:13baf2e4-b655-418e-985a-ca0d4c25baf9,d:e5d08777fcc842f4be32f3d12425f851-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gern-20250507</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0000886744</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gern-20250507.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-07</xbrli:startDate><xbrli:endDate>2025-05-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie5d08777fcc842f4be32f3d12425f851_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May&#160;7, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">GERON CORPORATION</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-20859</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">75-2287752</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IRS Employer Identification <br/>No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">919 E. HILLSDALE BLVD</ix:nonNumeric>., <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">SUITE 250</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">FOSTER CITY</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">CA</ix:nonNumeric>LIFORNIA <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">94404</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">473-7700</ix:nonNumeric> </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">GERN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div id="ie5d08777fcc842f4be32f3d12425f851_13"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Results of Operations and Financial Condition</span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;7, 2025 Geron Corporation (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2025 and recent business highlights. A copy of the press release is attached as Exhibit 99.1.</span></div><div style="margin-bottom:20pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be &#8220;furnished&#8221; and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and shall not be incorporated by reference into any filing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">made by the Company with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div id="ie5d08777fcc842f4be32f3d12425f851_22"></div><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits. </span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits. </span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:8.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.480%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 2.44pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20250331xexx991.htm">Press release titled "Geron Corporation Reports </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20250331xexx991.htm">First </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20250331xexx991.htm">Quarter 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20250331xexx991.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20250331xexx991.htm"> Financial Results and Recent Business Highlights," dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20250331xexx991.htm">May </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20250331xexx991.htm">7, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="gern-20250331xexx991.htm">5</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL<br/>document)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie5d08777fcc842f4be32f3d12425f851_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GERON CORPORATION</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;7, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ Scott A. Samuels</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scott A. Samuels</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Legal Officer and<br/>Secretary</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>gern-20250331xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i19047c05ea1d49e2959dbd629dc15e24_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 99.1</font></div><div style="margin-bottom:10pt"><img alt="logo.jpg" src="logo.jpg" style="height:61px;margin-bottom:5pt;vertical-align:text-bottom;width:124px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Reported $39.4 million in RYTELO</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> (imetelstat) net product revenue in Q1 2025&#59; revenue impacted by inventory dynamics, with Q1 demand relatively flat</font></div><div><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Granted marketing authorization of RYTELO by the European Commission (EC)&#59; planning for commercial launch in select EU countries 2026 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed&#47;refractory myelofibrosis&#59; interim analysis remains expected in 2H 2026</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Company to host conference call and webcast today, May 7 at 8&#58;00 a.m. ET</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">FOSTER CITY, Calif., May 7, 2025 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211; Geron Corporation (Nasdaq&#58; GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the first quarter of 2025 and recent business highlights.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are confident in the long-term potential of RYTELO as an important therapeutic for eligible patients with lower-risk-MDS and are sharply focused on maximizing the U.S. commercial opportunity,&#8221; said Dawn Carter Bir, Interim President and Chief Executive Officer of Geron. &#8220;We have received positive feedback from clinicians who have utilized RYTELO, supporting its strong therapeutic profile. We&#8217;ve identified specific opportunities and are making focused investments that we believe will strengthen the U.S. commercial trajectory. We expect our increased commercial investments to bolster uptake across a broader group of prescribers and drive long-term demand. We are also expanding our medical affairs efforts to support increased awareness and education. Looking ahead, our Phase 3 IMpactMF trial evaluating overall survival with imetelstat in patients with JAKi relapsed&#47;refractory myelofibrosis (R&#47;R MF), which we believe represents a tremendous expansion opportunity, is progressing well and the event-driven interim analysis is still expected in the second half of 2026.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recent Business Highlights </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">Continued first year of U.S. commercialization of RYTELO, with net product revenue of $39.4 million in the first quarter of 2025.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Demand for RYTELO in the 13-week period through the week ending March 28 increased 1% compared to the prior 13 weeks.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">Received marketing authorization for RYTELO from the European Commission (EC) as a monotherapy for the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low, or intermediate risk myelodysplastic syndromes (lower-risk MDS or LR-MDS) without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (ESAs). </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.59pt">Launch planning is underway and Geron expects to commercialize RYTELO in select EU countries commencing in 2026. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">Reached 85% enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in patients with JAKi R&#47;R MF. We continue to expect an interim analysis readout for overall survival in the second half of 2026 (when approximately 35% of patient events have occurred), and final analysis in the second half of 2028 (when approximately 50% of patient events have occurred</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.59pt">The Company believes there is a significant market opportunity for imetelstat to treat JAKi R&#47;R MF patients based on its unique mechanism of action, strong clinical data to date, and the substantial size of the addressable patient population, if the trial is positive and imetelstat is approved in this indication. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.59pt">Clinical data from the Phase 2 study showed a strong signal regarding prolonged survival and resolution of bone marrow fibrosis in patients treated with imetelstat, suggesting the potential for disease modification.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:16pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter 2025 Financial Results</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March&#160;31, 2025, Geron had approximately $457.5 million in cash, cash equivalents, restricted cash and marketable securities, compared to $502.9 million as of December 31, 2024. </font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025, the Company reported a net loss of $19.8 million, or $0.03 per share, compared to $55.4 million, or $0.09 per share, for the three months ended March 31, 2024.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total product revenue, net for the  three months ended March 31, 2025, was $39.4 million. There was no product revenue in the prior year period, as RYTELO was approved by the FDA in June 2024. The decline in net product revenue compared to the three months ended December 31, 2024, which was $47.5 million, was primarily due to inventory drawdown among RYTELO distributors from the fourth quarter of 2024 into the first quarter of 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total net revenue for the three months ended March 31, 2025, was $39.6 million, compared to $0.3 million for the same period in 2024. Total net revenue includes license fees and royalties in addition to any product revenue, net. The increase in revenue is due to product revenue from U.S. sales of RYTELO, which was approved by the FDA in June 2024.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses for the three months ended March 31, 2025, were $56.3 million, compared to $56.4 million for the same period in 2024.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was approximately $1.2 million for the three months ended March 31, 2025, which consisted of costs to manufacture and distribute RYTELO, compared to nil in the prior year period.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses for the three months ended March 31, 2025, were $15.1 million, compared to $29.4 million for the same period in 2024. The decrease was primarily due to the wind down of clinical trial costs associated with a decrease of activity in our Phase 3 IMerge MDS study after FDA approval of RYTELO in 2024, as well as manufacturing and quality costs that were capitalized in the current period now that RYTELO is approved, versus being expensed in the prior year period.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Selling, general and administrative expenses for the three months ended March 31, 2025, were $40.0 million, compared to $27.1 million for the same period in 2024. The increase in general and administrative expenses in 2025 as compared to 2024 primarily reflects higher personnel expenses related to increased headcount to support commercialization of RYTELO in the U.S.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest income was $5.2 million for the three months ended March 31, 2025, compared to $4.2 million for the same period in 2024. The increase in interest income in 2025 compared to 2024 primarily reflects a larger marketable securities portfolio, with the receipt of net cash proceeds from synthetic royalty and debt financings in November 2024. Interest earned in future periods will depend on the size of our marketable securities portfolio and prevailing interest rates. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest expense was $8.2 million for the three months ended March 31, 2025, compared to $3.4 million for the same period in 2024. The increase in interest expense primarily reflects $4.8 million in non-cash interest expense related to our synthetic royalty agreement and an increased principal debt balance under our loan agreement and a prior loan agreement, which was repaid in the fourth quarter of 2024. Interest expense reflects interest expense recognized under the synthetic royalty agreement, interest owed under the loan agreements, as well as amortization of associated debt issuance costs and debt discounts using the effective interest method and accrual for an end of term charge. </font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025 Financial Guidance </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For fiscal year 2025, the Company maintains its previously announced expectations of total operating expenses to be in the range of approximately $270 million to $285 million, which includes non-cash items such as stock-based compensation expense, amortization of debt discounts and issuance costs, and depreciation and amortization. </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the current operating plans and assumptions, the Company believes that existing cash, cash equivalents, and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Geron will host a conference call at 8&#58;00 a.m. ET on Wednesday, May 7, 2025, to discuss business updates and first quarter 2025 financial results.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A live webcast of the conference call and related presentation will be available on the Company&#8217;s website at www.geron.com&#47;investors&#47;events. An archive of the webcast will be available on the Company&#8217;s website for 30 days.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Participants may access the webcast by registering online using the following link, https&#58;&#47;&#47;events.q4inc.com&#47;attendee&#47;810252487</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About RYTELO (imetelstat)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RYTELO is an oligonucleotide telomerase inhibitor approved in the U.S. for the treatment of adult patients with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, RYTELO is approved in the European Union as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission.</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Geron </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO&#8482; (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed&#47;refractory myelofibrosis (R&#47;R MF), as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or LinkedIn.</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About IMpactMF Phase 3</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IMpactMF is an open label, randomized, controlled Phase 3 clinical trial with registrational intent. The trial is designed to enroll approximately 320 patients with intermediate-2 or high-risk myelofibrosis (MF) who are relapsed after or refractory to prior treatment with a JAK inhibitor, also referred to as relapsed&#47;refractory MF. Patients will be randomized to receive either imetelstat or best available therapy. The primary endpoint is overall survival (OS). Key secondary endpoints include symptom response, spleen response, progression free survival, complete remission, partial remission, clinical improvement, duration of response, safety, pharmacokinetics, and patient reported outcomes. IMpactMF is currently enrolling patients. For further information about IMpactMF, including enrollment criteria, locations and current status, visit clinicaltrials.gov&#47;study&#47;NCT04576156.</font></div><div><font><br></font></div><div style="margin-bottom:20pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMPORTANT SAFETY INFORMATION ABOUT RYTELO</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">WARNINGS AND PRECAUTIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Thrombocytopenia</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RYTELO can cause thrombocytopenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased platelets occurred in 65% of patients with MDS treated with RYTELO.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Monitor patients with thrombocytopenia for bleeding. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer platelet transfusions as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Neutropenia</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RYTELO can cause neutropenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased neutrophils occurred in 72% of patients with MDS treated with RYTELO.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Monitor patients with Grade 3 or 4 neutropenia for infections, including sepsis. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer growth factors and anti-infective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Infusion-Related Reactions</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RYTELO can cause infusion-related reactions. In the clinical trial, infusion-related reactions occurred in 8% of patients with MDS treated with RYTELO&#59; Grade 3 or 4 infusion-related reactions occurred in 1.7%, including hypertensive crisis (0.8%). The most common infusion-related reaction was headache (4.2%). Infusion-related reactions usually occur during or shortly after the end of the infusion.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Premedicate patients at least 30 minutes prior to infusion with diphenhydramine and hydrocortisone as recommended and monitor patients for one hour following the infusion as recommended. Manage symptoms of infusion-related reactions with supportive care and infusion interruptions, decrease infusion rate, or permanently discontinue as recommended.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Embryo-Fetal Toxicity</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RYTELO can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RYTELO and for 1 week after the last dose.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ADVERSE REACTIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Serious adverse reactions occurred in 32% of patients who received RYTELO. Serious adverse reactions in &#62;2% of patients included sepsis (4.2%) and fracture (3.4%), cardiac failure (2.5%), and hemorrhage (2.5%). Fatal adverse reactions occurred in 0.8% of patients who received RYTELO, including sepsis (0.8%).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Most common adverse reactions (&#8805;10% with a difference between arms of &#62;5% compared to placebo), including laboratory abnormalities, were decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia&#47;myalgia, COVID-19 infections, and headache.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;pi.geron.com&#47;products&#47;US&#47;pi&#47;rytelo_pi.pdf.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding&#58; (i) the Company&#8217;s beliefs regarding the long-term potential of RYTELO as an important therapeutic for eligible patients with lower-risk MDS&#59; (ii) the strength of RYTELO&#8217;s therapeutic profile&#59; (iii) the Company&#8217;s beliefs, plans and expectations regarding specific opportunities and investments the Company is making, and the expected success of these efforts to strengthen the U.S. commercial trajectory and increase awareness and education across prescribers&#59; (iv) the Company&#8217;s beliefs and expectations regarding uptake of RYTELO across a broader group of prescribers and long-term demand, including as a result of the Company&#8217;s increased commercial investments&#59; (v) the Company&#8217;s beliefs regarding the significant market opportunity for imetelstat to treat JAKi R&#47;R MF patients if the Phase 3 IMpactMF trial is positive and imetelstat is approved in this indication&#59; (vi) the </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Company&#8217;s beliefs regarding the progress and status of the Phase 3 IMpactMF trial and expected timing for the interim analysis occurring in the second half of 2026 and the final analysis in the second half of 2028&#59; (vii) the Company&#8217;s plans and expectations regarding the timing for commercializing RYTELO in select EU countries in 2026&#59; (viii) imetelstat&#8217;s potential for disease modification&#59;   (ix) the Company&#8217;s projections for total operating expenses for fiscal year 2025&#59; (x) the Company&#8217;s expectations that it will reach profitability without additional financing if its current internal sales and operating expense expectations are met&#59; (xi) the Company&#8217;s projections and expectations regarding the sufficiency of its existing financial resources, together with U.S. sales of RYTELO, to fund its projected operating requirements for the foreseeable future&#59; (xii) that inhibiting telomerase activity aims to potentially reduce proliferation and induce death of malignant cells&#59; (xiii) that IMpactMF has registrational intent&#59; and (xiv) other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to&#58; (a) whether Geron is successful in commercializing RYTELO (imetelstat) for the treatment of certain patients with lower-risk MDS with transfusion dependent anemia and achieves market acceptance across the breadth of the eligible patient segments in RYTELO&#8217;s approved indication&#59; (b) whether the FDA and European Commission will approve imetelstat for other indications on the timelines expected, or at all&#59; (c) Geron&#8217;s plans to commercialize RYTELO in the European Union, or EU and risks related to operating outside of the U.S.&#59; (d) whether Geron overcomes potential delays and other adverse impacts that may be caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing and regulatory challenges in order to have the financial resources for and meet expected timelines and planned milestones&#59; (e) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds&#59; (f) whether any future safety or efficacy results of RYTELO treatment cause its benefit-risk profile to become unacceptable&#59; (g) whether imetelstat actually demonstrates disease-modifying activity in patients and the ability to target the malignant stem and progenitor cells of the underlying disease&#59; (h) whether Geron meets its post-marketing requirements and commitments for RYTELO&#59; (i) whether there are failures or delays in manufacturing or supplying sufficient quantities of RYTELO (imetelstat) or other clinical trial materials that impact commercialization of RYTELO or the continuation of the IMpactMF trial&#59; (j) that the projected timing for the interim and final analyses of the IMpactMF trial may vary depending on actual enrollment and death rates in the trial&#59; and (k) whether Geron stays in compliance with and satisfies its obligations under its debt and synthetic royalty financing agreements. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron&#8217;s filings and periodic reports filed with the Securities and Exchange Commission under the heading &#8220;Risk Factors&#8221; and elsewhere in such filings and reports, including Geron&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2024, and subsequent filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial tables follow.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i19047c05ea1d49e2959dbd629dc15e24_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GERON CORPORATION</font></div><div style="margin-bottom:20pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:71.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.143%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share and per share data)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.48pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,436&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.48pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">304&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,603&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">304&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.48pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,206&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.48pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,078&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,373&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.48pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,023&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,065&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,307&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,438&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,704)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56,134)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,152&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,200)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,433)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income and (expense), net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(83)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(62)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,835)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55,390)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and diluted net loss per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.48pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.03)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.09)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:54pt;text-indent:6.48pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares used in computing net loss per share</font></div></td><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">665,905,469</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">603,493,451</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i19047c05ea1d49e2959dbd629dc15e24_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Note 1)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.48pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85,610&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,876&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.48pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current marketable securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313,132&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">327,550&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.48pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97,027&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,566&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 17.56pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495,769&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490,992&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent marketable securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,795&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,519&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,147&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,310&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits and other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,739&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,960&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">562,450&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">593,781&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2.25pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,034&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,298&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231,178&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225,163&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">268,238&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">280,320&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">562,450&#160;</font></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:2.25pt solid #ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">593,781&#160;</font></td><td style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-indent:-58.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 1&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.48pt">Derived from audited financial statements included in the Company&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2024.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i19047c05ea1d49e2959dbd629dc15e24_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTACT&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investor&#64;geron.com</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">media&#64;geron.com</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#####</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>gern-20250507.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:36b68b42-154c-41c5-9cff-b46b921c2a16,g:13baf2e4-b655-418e-985a-ca0d4c25baf9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gern="http://www.geron.com/20250507" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.geron.com/20250507">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gern-20250507_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gern-20250507_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.geron.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>gern-20250507_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:36b68b42-154c-41c5-9cff-b46b921c2a16,g:13baf2e4-b655-418e-985a-ca0d4c25baf9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_98b620ad-0368-49a0-a989-162a9d6d12ae_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_af7353fe-ad5a-45e8-a6c6-fcedbd8e26d6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_97d33a63-677e-4781-8ce4-e30ce6e2ae38_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ceb37f2e-1653-46a3-8677-5fb89016edd8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_743f435b-ac4b-4792-8d3f-292266d18b89_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_1a71c181-0c42-48fb-8aca-b6bacf0393f3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9afb3b04-b4c0-4a8b-a2a4-a6f7da4f8dd7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f523fc41-86a7-4dfe-ae06-503a3846e370_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_6156c376-e96a-4125-9d68-7513fbf399a0_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_712135b4-2238-4d69-8f30-eaa2e4aec49c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_2405c9c9-adc7-42e5-af2a-df5e761dd306_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_bfeeb17f-f54c-4af7-be72-7fb77cbaf5e8_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_9e11b798-081a-44b9-88e5-91f1f7b8ec34_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9e0db3f3-2969-4f51-9f51-d78dce74a1a3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_da0d59a1-9a9f-4e30-91d0-36c52bacc8e7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3d4e3754-0d0c-4434-85f9-5e98adb93695_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_07ca6391-163b-40c9-84fa-bd1de01f142a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7f9d74ce-737c-4851-bdc3-71859be2e6e5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_94ecc485-1387-4d10-9bb5-bf77cf7acf2c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_db2f4120-e297-42ae-bb39-820782599b9b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3b409751-ac92-4278-a61d-40b849c17692_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_7c780be7-0bae-4017-aa23-62df7fb180c0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2330aea2-7e8d-449e-8984-99d7a24073f9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b0eb85ae-cdce-44bc-9f4b-9b5260f91bfd_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>gern-20250507_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:36b68b42-154c-41c5-9cff-b46b921c2a16,g:13baf2e4-b655-418e-985a-ca0d4c25baf9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.geron.com/role/Cover" xlink:type="simple" xlink:href="gern-20250507.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.geron.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cb189754-dca7-4a59-abdb-8620bad02692" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_DocumentType_cb189754-dca7-4a59-abdb-8620bad02692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c324ce49-308e-4ecd-af4e-b62cbe3db1f3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_DocumentPeriodEndDate_c324ce49-308e-4ecd-af4e-b62cbe3db1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4b979394-24d6-4be9-a351-3b5abd376027" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_EntityRegistrantName_4b979394-24d6-4be9-a351-3b5abd376027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_dc3fc38b-d7e4-4918-a8a3-b8f86c311c38" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_dc3fc38b-d7e4-4918-a8a3-b8f86c311c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_878b5ff2-427e-47ce-8842-51b916693ec3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_EntityFileNumber_878b5ff2-427e-47ce-8842-51b916693ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_73498471-177c-4888-950c-c70f0ad4e526" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_EntityTaxIdentificationNumber_73498471-177c-4888-950c-c70f0ad4e526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_33c5e213-c8fd-4160-ab46-ac3915a78207" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_EntityAddressAddressLine1_33c5e213-c8fd-4160-ab46-ac3915a78207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_ff1de2a4-6e60-4cf7-8dab-6b19692bd687" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_EntityAddressAddressLine2_ff1de2a4-6e60-4cf7-8dab-6b19692bd687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b35d7ec2-b50b-42d5-befb-48f8140e4a29" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_EntityAddressCityOrTown_b35d7ec2-b50b-42d5-befb-48f8140e4a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6ce65761-c099-4535-9db7-febc860a9b3b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_EntityAddressStateOrProvince_6ce65761-c099-4535-9db7-febc860a9b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d6b60438-fdab-40e9-a686-02957b06111c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_EntityAddressPostalZipCode_d6b60438-fdab-40e9-a686-02957b06111c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_49d48859-28d5-4eef-84e1-57556a7b283a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_CityAreaCode_49d48859-28d5-4eef-84e1-57556a7b283a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5a478f65-052d-473a-a5b5-6ff16f9b211c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_LocalPhoneNumber_5a478f65-052d-473a-a5b5-6ff16f9b211c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_77850774-0224-4bd6-96ac-ceedfa60ba64" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_WrittenCommunications_77850774-0224-4bd6-96ac-ceedfa60ba64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_03450333-170f-4052-9dc4-2764541d99e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_SolicitingMaterial_03450333-170f-4052-9dc4-2764541d99e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f2ca991b-f777-4d9b-b715-ef52c2d24ad2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_PreCommencementTenderOffer_f2ca991b-f777-4d9b-b715-ef52c2d24ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_18617da2-8075-4bb8-a8f4-c220d6397fd2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_18617da2-8075-4bb8-a8f4-c220d6397fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4fe01244-cfa5-4661-be94-d3f0fb3665b1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_Security12bTitle_4fe01244-cfa5-4661-be94-d3f0fb3665b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_88467a80-4fd9-4e59-8a19-96161acc0d78" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_TradingSymbol_88467a80-4fd9-4e59-8a19-96161acc0d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_06996247-b9e6-4386-b315-ea52c07eaaf3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_SecurityExchangeName_06996247-b9e6-4386-b315-ea52c07eaaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f3980186-00f5-4d58-9ede-db3f0213d4c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_EntityEmergingGrowthCompany_f3980186-00f5-4d58-9ede-db3f0213d4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6b868a00-a49a-458a-80be-11959fa9db79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_AmendmentFlag_6b868a00-a49a-458a-80be-11959fa9db79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bc8161e2-7f56-4430-a5dd-4ff12c6b6d12" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b262a369-fc8e-448a-b032-142a1d1c70a7" xlink:to="loc_dei_EntityCentralIndexKey_bc8161e2-7f56-4430-a5dd-4ff12c6b6d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -V!PX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBCM0!D:OK(TR6WB6+S99FP%SC ]?UK6]*X3[1_:_C*(]427">F
M$R?UQFN[Q7G8'$RQ$ZDOLIV1TXBDJ2BNMKL6BBBO1.8**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 G;->7ZM=?;-5N+@'*LQ"_0<#]!7H6L77
MV/2;F;."J$*?<\#]37F%?+\15_AI+U/7RNG\4SN/!:8TN9_[TQ_D*Z6L'PBN
MW04/]YV/Z_\ UJWJ]K+8\N%@O(X,4[UI>HM%%%=QSA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <QXSN-FGPVX/,CY/T _Q(KB*Z'QC<>9J
ML<0/$48S]2?_ -5<]7P><5O:8N7EH?1X"'+07F>B>%@!X=MSZES_ ./&MFL?
MPO\ \BY:_P# _P#T,UL5]E@?]VI^B_(\&O\ Q9>K US?B'6_[.US0+)7VF\N
MB&'JH4KC\W7\JZ3%>*_$35_+^(=M(IXTX1' _O [\_J*]+"TO:SY?)G!BZWL
MJ:?FCVNBFJ0R@@Y!Y!%.KG.I!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFW0]SHJO9WMMJ%K'=6DR2PR#*NAR"*L5Y+33LSV$TU="T444#"BBB@ HHHH
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M)XET*0X36=/8^@N4/]:OP75O<KF&>*4>J.&_E2<9+= IQ>S)Z*,T4BPHHHH
M**** "BBB@ HHHH **** "BBB@ I*,@=Q5"YUG3+3_CYU&TAQU\R95_F::3>
MQ+DENR_16$_C/PY'G=K5D<''RS!OY4S_ (3GPS_T&;;_ +ZJO93_ )61[>G_
M #+[SH**QH_%?A^4X76K#/H;A!_6M*"\MKI=UO<12KZHX8?I2<)+=%*I&6S+
M%%&:*DL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHS0 E%0SW=O;+NFGBB'J[A?YU0?Q+H49P^LZ>I]#<H/ZTU&3V1#G
M%;LU:*R/^$I\/_\ 0<T[_P "H_\ &K46K:;.<1:A:R'T693_ %IN$ET!3@]F
M7J*0,I&0>*6I+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI1=IH]BAB:=97BRU1116!TA1110 4444 %%%% !1110 4444 %%%% !1110
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M(^*[?Q1IOFJ!'=18$\.?NGU'L>U='7STX2A+EDCZ.$XSCS1>@M%%%26%%%%
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M?2/A[Q%8>(]/%U929Q@21M]Z-O0BMC%?-GA[Q#=^'-42]M6ROW98CTE7/3_
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MA:16MM&L<$2A41>@ JQ117SC=]6?2I)*R%HHHH&%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?@ZU9UQ+=9N'_P"!?=_\= KK:^9QE7VE9OHCZC TO9T4NKU%HHHKE.P****
M"BBB@ HHHH **** "BBB@ HHHH *JWUG#J%C-:7";HID*.OJ",&K-%"=G=":
M35F?,6K:=+H^K75A-]^WD*9Z9'8_B.:I5Z/\7-*%OK%IJ:# N8S&Y_VDQ@G\
M#^E><5]3AJGM*2D?)8FE[*JXA74?#[5#I7C&S).(KD_9W^C=/_'L5R].21HI
M%=&VNI#*1V(Y!JZL%.#@^I%*;A-270^J/>BJ>EWBZCI5I>K]V>%)1_P( U<K
MY1IIV9]?%II-"T444BA*Y_QS_P B3JW_ %P-=!7/^.?^1)U;_K@:TH_Q(^J,
MJW\.7HSYUHHHKZP^0"M+0M,;6M>L=.7<//E"L1U"CEC^0)K-KT3X1Z>)]?O+
MUAD6L(4>Q<\'\@U88FI[.E*1MAJ?M*L8GL<4200I%&H5$ 55'0 #I4E%%?+'
MUP4444 %%%% !1110 4444 %%%% !1110 E>9?%_31)I]AJ:K\T4AA<_[+#(
MS]"/UKTVN8^(%I]L\$:DN.8XQ*#Z;2"?T!KHPL^2M%^9S8N'/0E'R/GRBBBO
MJ#Y0*^@_A]>&]\$Z:Q.6C1H3[;25'Z 5\^5[3\(;CS/#%S$3S%=MCZ%5/\\U
MYN9QO13[,]+*I6K-=T>A4445X)]$%%%% !1110 4444 %%%% !1110 4444
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M_P#V='_"F#_T'O\ R3_^SKU:BCZ_B/YOP0?V?A_Y?Q9Y3_PI@_\ 0>_\D_\
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M 4444 %%%% !114<DB0Q-)(P5%!9F/  [F@#ROXPZH"^GZ4K?=S<2#_QU?\
MV:O+*UO$NKMKOB&\U#YO+DDQ$#V0<+^@K*KZ?"TO9THQ9\GBZOM:LI(2BE/6
MMOP?IAU?Q7I]J1F/S1))Z;5^8_GC%;3DHQ<GT,:<'.2BNI[WH%@=,T#3[(C#
M0P(KCWQS^M:= H%?)R;;;9]A%**44+1112*$KG_'/_(DZM_UP-=!7/\ CG_D
M2=6_ZX&M*/\ $CZHRK?PY>C/G6BBBOK#Y .QKW3X5_\ (EQ_]=W_ )UX7V->
MZ?"O_D2X_P#KN_\ .O.S/^"O4]'*OX_R.WHHHKP#Z,**** "BBB@ HHHH **
M** "BBB@ HHHH 2JFJ_\@F\_ZX/_ .@FK=5-5_Y!-Y_UP?\ ]!-./Q(F?PL^
M8****^N6Q\:]PKU3X,?>UOZ0?^U*\KKU3X,?>UOZ0?\ M2N/,/\ =W\OS.S+
MO]XC\_R/5Z***^</J HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *R->U8:7997!GD^6-?Z_A6JQ"J23@
M#DFO-=8U!M2U*2?/[L?+&/0=OSZUM0I\\M3&M/ECH469I'+N69F.6)ZDFDHH
MKTCSSK?!)XO4]"A_/=_A76G[IKC?!;XN[J/^\@;\C_\ 7KLNU>;B/XC/0H?P
MSR_4[7['J=Q!MP$<[?\ =/(_0U4KI_&5ILO(KM1Q(NP_4=/YUS%=E*7-!,^>
MQ%/V=240HHHK0Q%!(((X(Y!KU.TG%S:0S#HZ*_YC->5UZ!X6N//T2,$Y:,F,
M_@?\*Y<2O=3/2RR=IN'<W****XSVRO=P"YM)H3TD1D_,5Y4RE'*L,,#@CW%>
MN5YGKUO]FUNY3& S;Q]#S_6OFN(J-X1J+T/5RN?O2@9U%%%?)GLA1110 444
M4 ':NW\'W_G6+6;GYX3D?[I_^O7$5HZ%>_8-6AD)PC'RW^A_^OS7HY7B?J^(
MC)[/1G-C*/M*378],KRGXP:1\UAJZ#UMY#^97_V:O5ATK(\3:0NN>'KRP(^:
M2,F,^CCE3^8K]&PM7V=53/D<72]K2<3YLHIS*R.5888'!!Z@TVOJCY0*[[X2
MWOD>*9K8M\MQ;L /5E((_3=7 UT/@6Y^R>-=*DSC=-Y?_?:E?ZUABH\U&2\C
M?"RY:T7YGT51117RQ]:%%%% !1110 4444 %%%% 'AGQ-\.G2?$!OX5Q:WQ+
M\=%D_B'X_>_.N'KZ2\1Z%!XAT2XL9L L-T;XSL<=&_SVKYVO[&XTZ_FLKJ/9
M/"Q1E]_4>QZBOH,OQ'M(<CW1\WF&&]E4YULRM1117H'GGI/PZ\<+I[1Z+JDF
M+5CBWF8\1DG[K'TST/;Z=/8,\<5\K5Z'X+^(TFE)'IVL%Y;(86.<<M$/0]R/
MU%>1C<"VW4I_<>Q@<>HKV=3[SV@4F*@M;N"]MTN+:9)H9!E7C8$$>QJQFO&V
MT9[:=]4%%%% PHHHH **** "BBB@ HHICNL:%F8*JC))X % #LUP'C[QRNBP
M-IFFR@ZC(,.XY\A2.O\ O'M^=9_C'XF)$)-/T!U>7[KW?55_W/4^_3TS7DSR
M-([.[LSL268G))/4DUZN#P+DU.IMV/'QN8))PI?>(27));)/))ZDTE%%>V>&
M%=#X.\-R>)==CMR"+6+#W##LOIGU/2LC3K"ZU6_ALK.,R3RG:JC^9] .YKZ#
M\+>'+?PSI"6<6'E/S32XP78]_IV K@QV*5&'*GJSOP.$=:=Y?"C:CC2&-8T4
M*B@* .  .@J2BBOGCZ4**** "BBB@#P_XI:-_9_B1;]$Q#?+N)'3S%P"/Q&#
M7"5]"^-]!_X2#PW/!&N;F+][!Z[AV_$9%?/1!!P>".HKZ'+ZWM*5GNCYK,*'
MLZW,MF%*K%"&4D,#D$<$&DHKO. ^A/!/B1?$F@QRN?\ 2X<17"]]P'WOH1S7
M35\X>%_$5QX:UB.\CW-"WR31?WTS_,=17T'IVHVNJV$5Y9RK)#*NY6'\O8^U
M?.8W#.E.ZV9]+@<4JT+/=%VBBBN([PHHHH **** "BBB@ HHHH **** "BBB
M@!*!56^OK;3K*6[NY1%!$NYG;L*Y;PQ\0=/\17TMDZ-:S[CY"N?]:O;'H<=1
M^57&E.47)+1&4JT(R4)/5G:4445!J%%%% !1110 4444 ?/WQ'_Y'[5/K%_Z
M*6N5KJOB/_R/VJ?6+_T4M<K7U.&_@P]$?(XG^-/U85U_PR_Y'JR_W)/_ $ U
MR%=?\,O^1ZLO]R3_ - -&)_@R]&/"_QH>J/?****^6/K0HHHH **** "BBB@
M HHHH **** "BBB@!,<5\\^.=&.B>*KN%4Q!.?/A],,>1^!R*^AZX7XG>'_[
M6\/_ &V!<W5CF08ZM'_$/TS^%=F!K>RJJ^S.#,*'M:5UNCPZBBBOI#YHGM+J
M:QO(;JW<I-"P=&'8@U]&>'=;@\0Z+!J$.!O&)$S]QQU4_P">E?-E=5X'\6/X
M9U3$S,UA<$+,@YVGLX'KZ^HK@Q^&]K"\=T=^ Q7L9\LMF?0-%10317,"30R+
M)%( RNIR"#T-2U\\?2A1110 4444 %%%% !1110 4444 %%%% "5YY\4?$JZ
M?I/]D6[_ .DW8_>8ZK'W_/I],UU?B/7[3PYI,E]=-DCB.,'!D;L!_GI7SSJF
MI76KZE/?WC[IYFW-Z =@/8#@5Z& PSJ3YY+1'F9CBE3C[.+U93HHHKZ ^>"O
M6/A#HQ6*\UF5>7_<0D_W1RQ_/ _X#7F%A8SZE?P65LFZ:=@BCW]3["OI+1M,
MAT;2;73X/]7!&$!]3W)^IYKS,RK\L%377\CT\LH<]3G>R-"BBBO"/H0HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 5RWB3XH:?IRM;Z3MOKKIO'^J4_7^+\./>O(M3U6^UB^:[O[AYIF[GH!Z =
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M_M5OK&:W;I(I /H>QKBIRY9)G1B*?M*;B>6T4Z5&BD:-QAT)5AZ$=:;7IGS
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MRV/I,-AH4(V6XM%%%<YTA1110 4444 ?/WQ'_P"1^U3ZQ?\ HI:Y6NJ^(_\
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M_P!=W_G7A?8U[I\*_P#D2X_^N[_SKSLS_@KU/1RK^/\ ([>BBBO /HPHHHH
M**** "BBB@ HHHH **** "BBB@!*J:K_ ,@F\_ZX/_Z":MU4U7_D$WG_ %P?
M_P!!-./Q(F?PL^8****^N6Q\:]PKU3X,?>UOZ0?^U*\KKU3X,?>UOZ0?^U*X
M\P_W=_+\SLR[_>(_/\CU>BBBOG#Z@**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^'WOTKF;BTN;.3R[F"6!_P"[*A4_D:[X583^%W//G1J0^)6(J***U,PHHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1=)MM/MQ\D*;<GJQ[D_4\UHT45XC;;NSWHI122%HHHI%!1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"8?V,-=WN+1117,=84444 %%%% !1110 4444 )7F'QBM"]EI=Z!Q'*\1/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJHJJJX4< #M3Z^[P6"AA::C'?JSYS$5Y5I\TA:***[3 **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!O45X;\0?!S:%?G4+./_B77#=!TA<_P_0]
MORKW3M5>[M+>_M)+6ZB66&0;71N0171AL1*C/F1RXK#1KPY7N?+E%==XT\$W
M/AFZ-Q;J\NFR'Y).IC/]UOZ'O7(U]'2JQJQYH,^9JTITY<L@HHHK4S.N\/?$
M/6-""0N_VVT7CRIB=RCT5NH_'(KT_1?B'X?U<*K77V.<_P#+.YPGY-]T_GFO
M J*XJ^ I5==F=U#'U:6FZ/JA7610RLK*>01SD4ZOF33M<U326S8W]Q;CKM1S
MM/U7H?RKJK/XJ^(K50)S:W8[F2/:W_CI _2O.GEE5?"[GHPS6D_C5CW'-%>4
MV_QD/ N=&^K1S_T*_P!:OI\8=*(&_3KT'OC:?ZUSO UU]DZ5C\._M'H]%>>M
M\7]# ^6RU GT*(/_ &>J\OQATX?ZG3+IC_M,J_RS26$KO[(WCL.OM'I=)7DE
MQ\9+A@1;:-&GH9)RWZ!1_.L2\^*/B:ZR(IK>T!_YXP@G_P >S6L<NKO=6,I9
ME06SN>Z,Z1J69E51R2>,5RVL?$/P]I(9?M8NYATCMOG_ /'ONC\Z\.OM9U+5
M#F^O[BY]%DD)4?0=!5&NNGE:6M21Q5<VD](([77_ (E:SJX:&U_T"V/&(B2[
M#W;_  Q7%L<\GK245Z5*E"FK05CS*E:=1WD[A1116IF+7=_#OP:VLWBZI?1_
M\2^!LHK#B9P?U4'_  ]:K^"_ =QXAF2\O5:'3%.<]&F]E]O?\J]PMK:&TMTM
M[>-8X8P%1%&  *\K'8Q17LZ>YZN P+F_:3V)^U%%%>(>^%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 )63KVEC4[ A1^_CRT9]_3\:UZ2G&3B[H32:LSR8@@D$8(X(
M-=OX/?=I,BG^&8X^F :RO%>F?9[H7L8Q%*<.!V;_ .O5_P %D?9;H=Q(I_,5
MVU9*=+F1QTXN-2S.HK@_%T>W60W]^)3^.2/Z5WAZ5Q/BV.276;>-1DO&JK[L
M6/%84/C#'QO1^9L>$[;R='$A',SEOPZ#^59OC.^_U%DI_P"FC_T_K73P1I8V
M"(6Q'#&!N/H!UKS34;QK_4)KEOXV^4>@'0?E7SV?XODHN"WE^1[&48;57VBO
MQ*U%'-=5H/AAI-MW?IA.J0GOZ%O\*^3PF$J8F?)37_ />KUX48\TBOH'AUKU
MDNKM=MN.50\%_P#ZU=PJA%"J,*. !VIP&.!2U]S@L%3PL.6._5GSM?$3K2YI
M"T445VF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 0S017,#PS1K)$X*LK#((]Q7DWBSX7S0-)>Z"IEBZM:$Y9?]TGJ/8\_6O7J*
MVH8B=&5X,YZ^'A6C:2/E=T>*1XY$9'4D,K+@@CJ"*;7T5X@\':1XC0FZ@"7&
M,+<1_*X_'N/K7EFN?#'6M++2V2C4+<<_N^) /=>_X$U[=#,*=326C/"Q&7U:
M>L=4<113YH9()FBFC>.13AD8%6!]Q3*[[G!:P4444 %%%% !1110 4444 %%
M%% !15FQL+S4IA#96LMQ(>T:%C^/I7>Z'\)K^Y99=8G%I%WBB(>0_C]T?K6%
M3$4J2]YFU+#U:KM%'GUM:SWMPL%M"\TSG"QH"S$^PKU3PI\+1$T=[K^UW'S+
M:*<J#_MGO]!Q7=:+X<TOP_!Y6GVJ1DC#2$9=OJW6M>O(Q.82G[L-$>UALMC"
MTJFK&(BQ($10J*  H& !]*DHHKS3U HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU@BAB'18T"@?@*GHHS7->^YU)6T0M%%% PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *BEC6:%XVSM<%3C@X-244FDU9@0P6\5M&(H8U
M1%Z*HP*FHHH225D#;;NQ:***8!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  07,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GERON CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-20859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">75-2287752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">919 E. HILLSDALE BLVD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">FOSTER CITY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">473-7700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GERN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +0XIUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( +0XIUJ=38Q3[@   "L"   1
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M<;>>*7[MP_!PF%^'70^/ ]B?3=?K,_G#]6K)2N=W<:/^CFR<IAF0U0+BLG6
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M$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( +0XIUJ7BKL<P
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MCEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0    ( +0XIUHD'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ M#BG6IU-C%/N    *P(  !$
M             ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MM#BG6IE<G",0!@  G"<  !,              ( !X $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "T.*=::(' 6UT$   4$0  &
M    @($A"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MM#BG6I^@&_"Q @  X@P   T              ( !M P  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " "T.*=:EXJ[',     3 @  "P              @ &0
M#P  7W)E;',O+G)E;'-02P$"% ,4    " "T.*=:JL0B%C,!   B @  #P
M            @ %Y$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ M#BG
M6B0>FZ*M    ^ $  !H              ( !V1$  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ M#BG6F60>9(9 0  SP,  !,
M         ( !OA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  "!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="gern-20250507.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="gern-20250507.htm">gern-20250507.htm</File>
    <File>gern-20250507.xsd</File>
    <File>gern-20250507_lab.xml</File>
    <File>gern-20250507_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "gern-20250507.htm": {
   "nsprefix": "gern",
   "nsuri": "http://www.geron.com/20250507",
   "dts": {
    "inline": {
     "local": [
      "gern-20250507.htm"
     ]
    },
    "schema": {
     "local": [
      "gern-20250507.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "gern-20250507_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gern-20250507_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.geron.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20250507.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20250507.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.geron.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000886744-25-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000886744-25-000007-xbrl.zip
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M-9"AJ+(_!7'O(;@JC,"6 PDC:= A\)-?0  J<H?(,;\Q1H#!(YI=FI28AEE
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M!N 0 7,*C. -A#VUC-64AW2&":^C%4L6)4R',FX17QB2<W%O?"N;1#MJF*5
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MO8:=4]"XML%H5RJ69:D#'V%"  J] OG:V'@XM61%T7&[&6C+@'+#HTY$>C1
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M/&JN(B=6B=1OVL3.YTRHN,%34B(E+!D]$<DGF9=#UB7XW:7:GPG.G=#G+JQ
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M7&B7GBGFN+*0 W(DA''@"4<$!=(6:=#$Z<?S[?S=HL.]_-L4]E?UIP7>&,/
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M(AU7.3QK=A@%$^X^CA=S9S2\63P1\0P/'.W=G^C^=/\B<;3W/U!+ 0(4 Q0
M   ( +0XIUID!Y??&28  (<D 0 8              "  0    !G97)N+3(P
M,C4P,S,Q>&5X>#DY,2YH=&U02P$"% ,4    " "T.*=:]I/RNIH/   =:@
M$0              @ %/)@  9V5R;BTR,#(U,#4P-RYH=&U02P$"% ,4
M" "T.*=:GIS^T5P"  #P!@  $0              @ $8-@  9V5R;BTR,#(U
M,#4P-RYX<V102P$"% ,4    " "T.*=:,E,JCG@*   )60  %0
M    @ &C.   9V5R;BTR,#(U,#4P-U]L86(N>&UL4$L! A0#%     @ M#BG
M6M@@8#'2!@  \C(  !4              ( !3D,  &=E<FXM,C R-3 U,#=?
=<')E+GAM;%!+!08     !0 % $H!  !32@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>gern-20250507_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gern-20250507.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0000886744</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-05-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">GERON CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-20859</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">75-2287752</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">919 E. HILLSDALE BLVD</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">SUITE 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">FOSTER CITY</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">473-7700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">GERN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
